FDA Issues Import Alert 89-04 in October 2026 for Six Categories of Olympus Endoscopic Devices Made in Japan: Shipments May Be Refused at the Port of Entry

News: FDA Issues Import Alert 89-04 in October 2026 for Six Categories of Olympus Endoscopic Devices Made in Japan

Published: October 21, 2026, 09:31 — Registration and Market Access

One letter and one import alert, issued back to back

On October 19, 2026, the U.S. Food and Drug Administration (FDA) issued Import Alert 89-04, designated as DWPE — Detention Without Physical Examination. The following day, October 20, 2026, the FDA issued a Letter to Health Care Providers explaining that the import alert applies to certain devices manufactured in Japan by Olympus Medical Systems Corporation and its subsidiaries. Both actions point to the same outcome: shipments on the alert list may be refused at the U.S. border on entry, without waiting for a problem to emerge after the device has been marketed and used.

Which devices are covered

According to the FDA's Letter to Health Care Providers, six product categories are involved:

• Ureterorenoscopes, used for the diagnosis and treatment of urinary tract conditions;
• Bronchoscopes, used for the diagnosis and treatment of respiratory tract conditions;
• Laparoscopes, used for abdominal and pelvic diagnosis and treatment;
• Automated endoscope reprocessors (AERs), used for endoscope reprocessing;
• Ingestible gastrointestinal capsule imaging systems, used to visualize the mucosa of the small intestine; and
• Enteroscopes, used for examination and procedures in the small intestine.

The FDA has also published a list identifying the affected devices line by line by model and Unique Device Identifier (UDI). The list carries an effective date of June 24, 2025.

On what basis may entry be refused

The product description in Import Alert 89-04 refers to “all medical devices” and targets firms that have not met device quality system requirements. The charge is based on Section 801(a)(1) of the Federal Food, Drug, and Cosmetic Act: the methods, facilities, or controls used for manufacturing, packing, storage, or installation do not conform to the requirements of Section 520(f)(1), and the devices are therefore adulterated within the meaning of Section 501(h). The corresponding OASIS charge code is DEVICEGMPS. For firms placed on the Red List, ports may detain their products without conducting a physical examination.

What is required to be removed from the list

Under the guidance in the import alert, a firm must provide the FDA with information sufficient to demonstrate that the conditions giving rise to the violation have been resolved before the agency will consider removing the product from the Red List; the procedure follows Chapter 9-8 of the Regulatory Procedures Manual. Submissions are made through the designated email address, and import-operational questions are handled by the FDA's Division of Import Operations. Explaining a position is not sufficient. What the FDA expects is documentation showing that the problem has actually been corrected. The difference between the two is substantial.

What is not covered is equally important

The FDA explicitly states that the import alert does not apply to replacement parts, connectors, or single-use accessories used with the listed devices. Devices already in use may continue to be used if no problems have arisen during use. Users should perform cleaning and disinfection in accordance with the labeling and reprocessing instructions, and accessories must be reprocessed as well. Devices that are damaged, or that fail a leak test, must not be used. Routine inspection and scheduled maintenance should be carried out according to the manufacturer's instructions. Some devices subject to the import alert may also be under recall, in which case the firm's customer notification should be followed. The FDA does not recommend canceling or postponing procedures without a discussion between clinician and patient; rather, it asks that the benefits and risks be clearly explained.

The FDA's own wording on remediation status

The Letter to Health Care Providers states that, despite substantial and ongoing work by the firm to address compliance issues, the agency remains concerned about unresolved quality system violations and is therefore issuing the import alert to prevent the affected devices from continuing to enter the United States. The letter also notes that prior warning letters and import alerts concerned current good manufacturing practice requirements and multiple reporting obligations, including recalls that the FDA classified at its most serious level. The FDA states that it will continue to monitor the firm's corrective actions and will update its communications as new information becomes available.

Where the difference in severity lies

A warning letter is addressed to the firm; an import alert is addressed to the ports. The former requires corrective action; the latter directly determines whether goods may enter the country. For manufacturers located outside the United States and exporting to the U.S. market, an unresolved finding from a quality system inspection may not stop at the level of correspondence — it can become a model-level barrier at the border, and that barrier attaches to the shipment, not to the clearance or registration. The list is organized by model and UDI. Different product lines from the same manufacturer may be treated differently. Verify the model first; everything else follows.

Sources and scope notes

Sources: U.S. Food and Drug Administration, Import Alert 89-04, “Detention Without Physical Examination of Devices from Firms that Have not met Device Quality System Requirements,” https://www.accessdata.fda.gov/cms_ia/importalert_241.html, issued October 19, 2026; U.S. Food and Drug Administration, Letter to Health Care Providers, “Import Alert for Certain Olympus Medical Devices Manufactured in Japan,” https://www.fda.gov/medical-devices/letters-health-care-providers/import-alert-certain-olympus-medical-devices-manufactured-japan-letter-health-care-providers, issued October 20, 2026; U.S. Food and Drug Administration, CDRH New – News and Updates, https://www.fda.gov/medical-devices/medical-devices-news-and-events/cdrh-new-news-and-updates, consulted to verify the publication date.

Verification scope and access date: the pages above were accessed on October 21, 2026. Verification covered the import alert number, type, issue date, statutory charge and removal procedure, as well as the six device categories listed in the Letter to Health Care Providers, the list's effective date, and the wording describing the exclusions. Individual model numbers and UDIs on the list are not reproduced item by item here; the official list should be relied upon in practice.

Scope note: this article is an interpretation of publicly available regulatory information and does not constitute a conclusion or commitment regarding any specific product, company, or registration application. Applicability is governed by the official texts and lists, and the information may change with subsequent official updates.

Information sources

• U.S. Food and Drug Administration — Import Alert 89-04, October 19, 2026
• U.S. Food and Drug Administration — Letter to Health Care Providers: Import Alert for Certain Olympus Medical Devices Manufactured in Japan, October 20, 2026
• U.S. Food and Drug Administration — CDRH New: News and Updates, October 20, 2026

AIMEILI Regulatory Interpretation

Import Alert 89-04 is a border-enforcement instrument, not a product-safety finding tied to a specific clinical adverse event. Its legal foundation is a quality system nonconformity elevated to an adulteration charge under Sections 801(a)(1), 520(f)(1) and 501(h), with the OASIS code DEVICEGMPS. The practical consequence is that FDA district offices and ports may detain affected entries without physical examination, shifting the burden of proof onto the importer and manufacturer before the goods are released. Three technical points deserve particular attention for regulatory affairs teams.

First, the unit of enforcement is the model and UDI, not the establishment or the 510(k). The Red List identifies specific devices by model and UDI, with an effective date of June 24, 2025. This means that the same legal manufacturer may have some lines detained and others cleared, and that a firm's broader portfolio or certificate status does not resolve the question. Importers should screen purchase orders and ASNs against the official list at the model and UDI level before shipment, not after arrival.

Second, DWPE reverses the ordinary evidentiary sequence. Under a standard entry review, the agency must articulate a basis for detention. Under DWPE, the entry is subject to refusal without examination unless the firm has been removed from the Red List. Removal requires affirmative documentary evidence that the conditions giving rise to the violation have been corrected, submitted through the designated channel and assessed under Regulatory Procedures Manual Chapter 9-8. Corrective action plans, responses to Form 483 observations, and warning-letter close-out correspondence are the operative evidence; assertions of intent or explanations of context are not.

Third, the alert is intentionally narrow in scope but not in effect. Replacement parts, connectors and single-use accessories are outside the alert, and devices already in clinical use may continue to be used if functioning properly and reprocessed per labeling. This carve-out does not, however, mitigate commercial disruption at the border, nor does it resolve the separate obligation to follow any overlapping recall communications. Where a device is both subject to the import alert and under recall, the firm's customer notification governs field action.

Business Impact

Supply continuity. Any distributor, GPO, IDN or OEM sourcing the listed models from Japan should model a hard stop at the U.S. port of entry rather than a delay. There is no routine pathway to obtain release of a Red List entry; substitution, allocation of unaffected models, and interim inventory planning are the realistic levers. Service and consumable channels are less exposed because accessories and replacement parts fall outside the alert, but that exemption should be confirmed against the official list rather than assumed.

Contractual and quality exposure. Import alerts frequently trigger contractual quality agreements' notification clauses, supplier corrective action requests and audit rights. Firms that rely on the affected manufacturer as a critical supplier should activate supplier-quality escalation, document risk assessment under their own QMS, and consider whether change control or field-action evaluation is required. Buyers should also verify that any certificates of conformity or free-sale documentation they hold remain operationally meaningful at the border.

Clinical and regulatory communication. Health systems should expect questions from clinicians about devices already in use. FDA's stated position is that procedures should not be canceled or postponed without clinician-patient discussion of benefits and risks, and that damaged or leak-test-failing devices must be withdrawn from service. Regulatory affairs teams should prepare consistent, source-referenced talking points rather than improvised guidance.

Lessons for non-U.S. manufacturers and their regulatory partners. The Olympus case illustrates the escalation path from inspectional observations to warning letter to import alert, and confirms that unresolved quality system findings can convert into model-level entry barriers without any new adverse event. Manufacturers exporting to the U.S. — including those in China, Southeast Asia and Europe — should treat open 483 observations and warning-letter commitments as market-access risk, not merely compliance paperwork, and should maintain ready evidence of closed-loop correction in a form that can be submitted for Red List removal if needed. For distributors and CROs supporting global registration, the practical implication is that U.S. market access depends on QMS closure evidence as much as on clearance decisions, and that entry planning should include a documented contingency for border refusal.